Xencor (NASDAQ:XNCR) insider Edgardo Baracchini, Jr. sold 40,000 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $30.89, for a total transaction of $1,235,600.00. Following the completion of the sale, the insider now directly owns 40,000 shares in the company, valued at $1,235,600. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ XNCR opened at $28.41 on Friday. The firm has a market cap of $1,547.62, a P/E ratio of -27.06 and a beta of 1.51. Xencor has a 12-month low of $18.55 and a 12-month high of $34.63.
Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. The business had revenue of $10.94 million for the quarter, compared to analyst estimates of $15.65 million. Xencor had a negative net margin of 137.35% and a negative return on equity of 16.62%. analysts predict that Xencor will post -2.09 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can lifted its stake in shares of Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Xencor in the third quarter valued at $201,000. UBS Asset Management Americas Inc. bought a new position in shares of Xencor in the fourth quarter valued at $205,000. Landscape Capital Management L.L.C. bought a new position in shares of Xencor in the fourth quarter valued at $220,000. Finally, Two Sigma Advisers LP bought a new position in shares of Xencor in the fourth quarter valued at $278,000. 79.49% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on XNCR shares. BidaskClub raised shares of Xencor from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Cantor Fitzgerald started coverage on shares of Xencor in a research note on Thursday, February 22nd. They issued a “buy” rating and a $33.00 price objective on the stock. Wedbush upped their price objective on shares of Xencor from $38.00 to $39.00 and gave the company an “outperform” rating in a research note on Monday, March 19th. Finally, Zacks Investment Research raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Tuesday, February 20th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $35.17.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/edgardo-baracchini-jr-sells-40000-shares-of-xencor-inc-xncr-stock.html.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.